An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

NCT05295433

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	ModernaTX, Inc.
Enrollment	56 participants

Key Eligibility Criteria

Inclusion (2)

- Completed the assigned dose regimen treatment time period in other clinical studies of mRNA-3705 or is eligible for early transition to this study because they missed more than 3 consecutive doses of study drug due to coronavirus disease 2019 (COVID-19) vaccination during Study mRNA-3705-P101 Part 1.
- Completed the End of treatment (EOT) Visit (or End of Study Visit in the case of unscheduled dosing) in Study mRNA-3705-P101 within 10 days of their first dose of mRNA-3705 in this extension study.

Exclusion (3)

- Not expected to receive clinical benefit from continued mRNA-3705 administration, in the opinion of the Investigator.
- Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.
- History of liver and/or kidney transplant.

Locations (12 total)

UCLA Medical Center, Los Angeles, California, United States
Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
Altman Clinical and Translational Research Institution, San Diego, California, United States
... and 9 more locations